Elevation Wealth Partners’s Neurocrine Biosciences NBIX Stock Holding History

Elevation Wealth Partners’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.36K	Buy	+14	New	+$2.08K	﹤0.01%	1175

Other funds holding NBIX

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

PBBUPS

PKO BP Bankowy Universal Pension Society Warsaw, Poland $350M AUM 272.18% 1-Year Est. Return

Aware Super Sydney, Australia $7.06B AUM

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Retirement Systems of Alabama Montgomery, Alabama $33.2B AUM 38.15% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

FAF

Fjarde Ap-fonden Stockholm, Sweden $20.9B AUM 36.93% 1-Year Est. Return

Elevation Wealth Partners's NBIX Position: Q2 2026 in Review

Elevation Wealth Partners opened a new position in Neurocrine Biosciences (NBIX) in Q2 2026: 14 shares worth $2.36K. The stake represents ﹤0.01% of the portfolio and ranks #1175 among its holdings.

219 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

Elevation Wealth Partners held 14 shares of Neurocrine Biosciences worth $2.36K as of Q2 2026.
Neurocrine Biosciences was a new Elevation Wealth Partners position in Q2 2026.
Neurocrine Biosciences made up ﹤0.01% of Elevation Wealth Partners's portfolio in Q2 2026, its #1175 holding.
219 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Elevation Wealth Partners's 13F filing for Q2 2026, filed 8 Jul 2026.